The canonical pyroptosis pathway is initiated by the assembly of inflammasome complexes, multi-protein platforms that activate caspase-1 (Flores et al., 2018): [@hu2020]
The non-canonical pathway is triggered by cytosolic lipopolysaccharide (LPS) and involves caspase-11 (mouse) or caspase-4/5 (human) : [@peng2020]
The gasdermin superfamily includes six members in humans, each with distinct tissue expression and activation mechanisms : [@shen2021]
| Gasdermin | Activating Protease | Expression in CNS | Relevance | [@sutinen2012]
|-----------|-------------------|-------------------|-----------| [@feng2022]
| GSDMA | Granzyme A | Limited | Skin diseases | [@ciccocioppo2020]
| GSDMB | Granzyme A, Caspase-1 | Low | Autoimmunity | [@ma2021]
| GSDMC | Caspase-8 | Low | Cancer | [@burnham2022]
| GSDMD | Caspase-1, -4, -5, -11 | [microglia | Primary CNS pyroptosis executor | [^12]
| GSDME | Caspase-3 | neurons | Secondary pyroptosis/necrosis |
| PJVK | Unknown | Inner ear | Hearing loss |
GSDMD is the primary executor of pyroptosis in the brain, expressed predominantly in [microglia. GSDME is notable because caspase-3 cleavage can convert apoptosis to pyroptosis in neurons, potentially contributing to inflammatory neuronal death link (Wu et al., 2024) [@shen2020].
Pyroptosis plays a significant role in the neuroinflammatory cascade of alzheimers. The nlrp3-inflammasome inflammasome] is a central mediator (Han et al., 2024):
Misfolded [α-synuclein/proteins/alpha activates the nlrp3-inflammasome inflammasome in both microglia/cell-types/microglia and neurons, initiating pyroptosis link (Li et al., 2025):
Robust GSDMD activation has been observed in ALS spinal cords:
The concept of PANoptosis describes the simultaneous activation of pyroptosis, apoptosis, and necroptosis through the PANoptosome, a multiprotein complex containing components from all three pathways. In the CNS, PANoptosis may explain why inhibiting a single death pathway often fails to protect neurons [@hu2020].
Caspase-3 cleavage of GSDME can convert apoptotic cell death to pyroptotic cell death in neurons, amplifying the inflammatory response. This is particularly relevant when:
ferroptosis and pyroptosis share upstream regulators including reactive oxygen species and iron metabolism. Mitochondrial oxidative-stress generated during ferroptotic stress can activate nlrp3-inflammasome, linking iron-dependent lipid peroxidation to inflammasome-driven pyroptosis [@peng2020].
Inhibiting pyroptosis represents an emerging therapeutic strategy for neurodegenerative diseases:
Recent studies suggest combination therapy targeting both GSDMD and immune checkpoint pathways. GSDMD inhibition combined with anti-PD-1 antibody synergistically reduced T-cell-mediated neuroinflammation in AD models [@shen2021].
The translation of pyroptosis research into clinical applications represents a promising frontier for neurodegenerative disease therapy. While preclinical evidence strongly supports targeting pyroptotic pathways, several challenges remain in translating these findings to human patients.
Inflammasome-Targeted Therapies
Multiple drug candidates targeting NLRP3 inflammasome activation have advanced to clinical testing:
MCC950 (CRID3): A potent, selective NLRP3 inhibitor that blocks ASC oligomerization. Preclinical studies in AD mouse models demonstrated reduced neuroinflammation, decreased amyloid plaque burden, and improved cognitive function (Roberts et al., 2019). MCC950 has undergone Phase I clinical trials for inflammatory conditions, establishing safety profiles applicable to CNS applications.
OLT1177 (Dapansutrile): An oral NLRP3 inhibitor that has completed Phase II trials for osteoarthritis and cardiovascular inflammation. Its favorable oral bioavailability and safety profile make it a candidate for neuroinflammatory indications (Marchetti et al., 2018).
Dapagliflozin: Originally developed for type 2 diabetes, this SGLT2 inhibitor demonstrates NLRP3 inflammasome suppression through AMPK activation. Post-hoc analysis of diabetes cohorts suggests reduced neurodegenerative disease incidence (Shen et al., 2020).
Gasdermin D Inhibition
Direct GSDMD targeting offers a more downstream approach:
Disulfiram: FDA-approved for alcohol use disorder, disulfiram covalently modifies GSDMD at Cys191, blocking pore formation. Retrospective clinical data suggests potential neuroprotective effects, though controlled trials are needed (Hu et al., 2020).
Dimethyl fumarate (DMF): Approved for multiple sclerosis, DMF succinates GSDMD at Cys191, inhibiting pyroptosis. Its established CNS penetration and safety profile support clinical investigation for AD and PD (Peng et al., 2020).
Core Pyroptosis Biomarkers
| Biomarker | Sample Type | Clinical Utility | Reference |
|---|---|---|---|
| IL-1β | CSF, plasma | Elevated in AD/PD; correlates with disease severity | (Shen et al., 2021) |
| IL-18 | CSF, plasma | Marker of inflammasome activation in neurodegeneration | (Sutinen et al., 2012) |
| GSDMD (cleaved) | CSF, plasma | Direct indicator of GSDMD activation | (Feng et al., 2022) |
| ASC specks | CSF | Inflammasome activation marker | (Ciccocioppo et al., 2020) |
| Caspase-1 activity | PBMCs | Peripheral immune activation | (Ma et al., 2021) |
Emerging Biomarker Candidates
Challenges in Biomarker Validation
Active and Completed Trials Targeting Inflammasome/Pyroptosis
| Drug | Condition | Phase | Status | NCT Number |
|---|---|---|---|---|
| Canakinumab (anti-IL-1β) | AD | Phase 2/3 | Completed | NCT02531534 |
| Anakinra (IL-1Ra) | AD | Phase 2 | Completed | NCT01699767 |
| VX-765 (Caspase-1) | Epilepsy | Phase 2 | Completed | NCT01501383 |
| OLT1177 | AD | Phase 1 | Recruiting | NCT05445323 |
Key Findings from Clinical Studies
Potential Benefits of Pyroptosis Inhibition
Disease Modification: Unlike symptomatic treatments, pyroptosis inhibition may slow disease progression by:
Symptomatic Improvement: Anti-inflammatory effects may provide:
Combination Potential: Pyroptosis inhibitors may synergize with:
Patient Populations Most Likely to Benefit
Major Challenges
Blood-Brain Barrier Penetration: Most inflammasome inhibitors have limited CNS penetration. Strategies under development include:
Timing of Intervention: Optimal intervention likely requires:
Pathway Specificity: Challenges include:
Biomarker Selection: Critical questions remain:
Future Directions
The execution of pyroptosis is primarily mediated by the gasdermin family of proteins, particularly gasdermin D (GSDMD). Upon activation by inflammatory caspases, GSDMD is cleaved to release its N-terminal domain, which oligomerizes and inserts into the plasma membrane to form pores. These pores are approximately 10-14 nm in diameter and cause cell swelling, membrane rupture, and release of intracellular contents including inflammatory cytokines[@liu2016][^18].
Gasdermin E (GSDME/DFNA5) provides an alternative cell death pathway that can switch apoptosis to pyroptosis. GSDME is cleaved by caspase-3, traditionally associated with apoptosis, and its N-terminal domain induces pyroptotic cell death. This pathway is particularly relevant in cancer, where chemotherapy-induced GSDME activation can promote anti-tumor immunity through inflammatory cell death[^19][@wang].
Microglial pyroptosis is a critical driver of neuroinflammation in neurodegenerative diseases. When microglia sense pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) through pattern recognition receptors, they activate the NLRP3 inflammasome and undergo pyroptosis. The release of IL-1β and IL-18 through gasdermin pores amplifies neuroinflammation and contributes to synaptic dysfunction and neuronal loss[@hene][@freeman].
In Alzheimer's disease, amyloid-β activates NLRP3 inflammasome in microglia, leading to caspase-1 activation and gasdermin D cleavage. The resulting pyroptosis releases pro-inflammatory cytokines that promote tau pathology and cognitive decline. Studies show that GSDMD deficiency in mouse models of AD reduces microglial activation and improves cognitive function[@yin2021][@jiang2020].
In Parkinson's disease, α-synuclein aggregates activate microglial NLRP3 inflammasome, triggering pyroptosis. The chronic release of inflammatory mediators from pyroptotic microglia creates a toxic environment for dopaminergic neurons. Inhibition of NLRP3 or GSDMD protects neurons in PD models, suggesting therapeutic potential[@lee2020][@gordon2018].
Targeting pyroptosis represents a novel therapeutic strategy for neurodegenerative diseases. NLRP3 inhibitors such as MCC950 and dapansutrile (OLT1177) block inflammasome activation and prevent pyroptosis. These compounds have shown promise in preclinical models and are being evaluated in clinical trials for inflammatory diseases[@coll2015][@marchetti2020].
Caspase-1 inhibitors such as VX-765 and pralnacasan prevent the activation of gasdermin D. While initially developed for inflammatory diseases, these inhibitors may benefit neurodegenerative conditions characterized by neuroinflammation. Gasdermin D inhibitors directly block pore formation and have shown protective effects in models of stroke and neurodegenerative diseases[@rathinam2021][@hu2020a].
Anti-inflammatory approaches targeting IL-1β (anakinra, canakinumab) and IL-18 have been evaluated in clinical trials for AD and PD. While results have been mixed, targeting the downstream effects of pyroptosis remains a promising strategy. Combination approaches targeting both inflammasome activation and gasdermin pore formation may provide maximal benefit[@green2021][@latz2021].
Pyroptosis can be detected and monitored through several approaches:
The study of Pyroptosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Dimension | Score |
|---|---|
| Supporting Studies | 12 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Co |
**Overall C---
Recent